Protein Information

ID 4345
Name pancreatic secretory trypsin inhibitor
Synonyms PCTT; PSTI; Pancreatic secretory trypsin inhibitor; Pancreatic secretory trypsin inhibitor precursor; SPINK 1; SPINK1; Serine protease inhibitor Kazal type 1; Spink3…

Compound Information

ID 388
Name butylamine
CAS 2-butanamine

Reference

PubMed Abstract RScore(About this table)
2310525 Coletta M, Ascenzi P, Bravin L, Amiconi G, Bolognesi M, Guarneri M, Menegatti E: Thermodynamic modeling of internal equilibria involved in the activation of trypsinogen. J Biomol Struct Dyn. 1990 Feb;7(4):959-72.
The effect of activating dipeptides, sequentially homologous to the Ile16-Val17N-terminus of bovine beta-trypsin (beta-trypsin), on equilibria involved in the binding of strong ligands (i.e., n-butylamine, the bovine basic pancreatic trypsin inhibitor (Kunitz-type inhibitor; BPTI) and the porcine pancreatic secretory trypsin inhibitor (Kazal-type inhibitor, type I; PSTI)) to bovine trypsinogen (trypsinogen) was investigated at pH 5.51 (I = 0.1 M) and T = 21.0 +/- 0.5 degrees C; under the same experimental conditions, thermodynamics for the binding of strong ligands to beta-trypsin was also obtained. The equilibria involved in the binding of activating dipeptides and/or inhibitors to beta-trypsin and to its zymogen are described according to an induced-fit formalism, taking into account ligand-linked interaction (s) between different functional and structural domains of the (pro) enzyme possibly involved in the trypsinogen-to-beta-trypsin activation pathway. The analysis of data is focussed on parameters describing interactions between the so-called Ile-Val pocket (where the Ile16-Val17 N-terminus of beta-trypsin or activating dipeptides bind) and the primary and/or secondary recognition subsite (s) (where strong ligands associate) present in the (pro) enzyme. Such an analysis allows to dissect the contributions due to the primary recognition subsite, where small mono-functional ligands (e.g., n-butylamine) bind, from those of the secondary subsite (s), which are additional recognition clefts for macromolecular inhibitors (e.g., BPTI and PSTI).
162(2,2,2,2)